Core Insights - The emergence of quantum computing within the AI sector is generating significant interest among growth investors, following the previous focus on traditional AI stocks [2][3] Industry Overview - The stock market's recent highs have been driven by artificial intelligence, with companies in the semiconductor and software industries leading the charge [2] - Quantum computing is now being recognized as a new growth area within the AI landscape, attracting attention from various sectors [2] Quantum Computing Significance - Quantum AI has the potential to revolutionize computing by utilizing qubits, which can exist in multiple states simultaneously, unlike traditional binary bits [4][5] - This capability allows quantum systems to model multiple outcomes concurrently, making them valuable for complex simulations in areas such as financial risk management and clinical research [5] Economic Impact - McKinsey & Company forecasts that quantum applications could contribute trillions in economic value over the coming decades, indicating a substantial market opportunity [6] Recent Developments - Alphabet has achieved a significant breakthrough with its Echoes algorithm in quantum AI, which is expected to enhance the relevance of quantum computing [10] - Despite Alphabet's advancements, other quantum computing stocks are receiving considerable attention in the market [10]

Core Insights - The weight loss and diabetes drug market is experiencing significant growth, driven by demand for effective treatments and new competitors entering the space [1][3] - Eli Lilly and Novo Nordisk remain the leading companies, with Eli Lilly gaining market share and accounting for nearly 60% of prescriptions in the injectable obesity and diabetes class [2][9] - The market is projected to reach approximately $100 billion by the end of the decade, with a potential 25 to 50 million U.S. patients using GLP-1s by 2030 [3][12] Market Dynamics - Eli Lilly has outperformed Novo Nordisk, increasing its market share from 53% in Q1 to 57% in Q2 of the current year, attributed to superior efficacy and safety of its drugs [9][10] - Novo Nordisk is facing challenges, including a nearly 40% drop in stock value this year and a need to cut its workforce by 11.5% to regain market footing [11][14] - The competition is intensifying, with many pharmaceutical companies investing in obesity drugs, often through partnerships with smaller developers [4][42] Access and Coverage Issues - Access to GLP-1s remains limited due to insurance coverage gaps, with many insurers not covering obesity treatments, leading to high out-of-pocket costs for patients [5][23] - Coverage for GLP-1s for obesity has slightly increased, with 36% of surveyed companies providing such coverage, up from 34% in 2024 [24] - Employers are hesitant to cover these high-cost drugs due to concerns about long-term patient adherence and potential weight regain [25][28] Future Developments - Both Eli Lilly and Novo Nordisk are working on oral formulations of GLP-1s, which could significantly change market dynamics and improve patient access [30][34] - Analysts predict that oral pills could capture around 24% of the weight loss drug market by 2030, with Eli Lilly expected to lead this segment [34][35] - The success of new oral treatments will depend on their pricing and effectiveness compared to existing injectable options [40][39] Competitive Landscape - The market is seeing a variety of new entrants and experimental drugs, with companies exploring different mechanisms for weight loss and less frequent dosing [41][42] - Novo Nordisk and Eli Lilly are also looking into new hormone-targeting treatments to expand their portfolios beyond current offerings [45][46] - The competitive landscape is evolving, with potential partnerships between smaller biotech firms and larger pharmaceutical companies to enhance drug development [51]

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ --Â Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The dividend will be paid on December 12, 2025, to all stockholders of record as of the close of business on November 21, 2025. About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's to ...

In the current session, Amgen Inc. (NASDAQ:AMGN) is trading at $291.80, after a 0.07% drop. Over the past month, the stock fell by 2.04%, and in the past year, by 7.92%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. Amgen P/E Compared to CompetitorsThe P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E ...

Accessibility StatementSkip Navigation Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy for Reducing Cardiovascular Events THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from t ...

Rep. Marjorie Taylor Greene (R-Ga.) purchased Netflix Inc. on Oct.24, just days after the streaming giant's stock tumbled following a disappointing third-quarter earnings report.Greene Loads On NFLX, Was She ‘Buying The Dip’?The purchase, valued between $1,001 and $15,000, was one of 14 new investments disclosed in a Periodic Transaction Report filed on Oct. 28.Netflix reported its earnings on Oct. 21, missing analyst expectations and causing its stock to drop significantly on Oct. 22. Rep. Greene's purchas ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $5.00 per share in its forthcoming report, representing a decline of 10.4% year over year. Revenues are projected to reach $8.94 billion, increasing 5.2% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prio ...

The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as of October 29, 2025The interchangeability (IC) designations of STOBOCLO and OSENVELT were granted based not only on the comparative clinical data - including pharmacokinetics, efficacy, safety and an immunogenicity study in postmenopausal women with osteoporosis[1] - but also on ana ...

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's seni ...

Key Takeaways Amgen will report Q3 results Nov. 4, with consensus estimates at $8.94B for sales and $5.00 for EPS.Strong volumes of Evenity, Repatha, Blincyto, and new drugs like Tezspire are likely to have supported sales.Patent expirations and biosimilar launches may have weighed on Prolia and Xgeva performance.Amgen (AMGN) will report third-quarter 2025 results on Nov. 4, before market open. In the last reported quarter, the company's earnings beat expectations by 14.5%. The Zacks Consensus Estimate for ...